NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

Saturday, November 4, 2023

7:30am – 3:30pm 

Earn up to 6.50 AMA PRA Category 1 Credits,™ Continuing Nursing Education (ANCC), and MOC accreditation

Register Now

Location

The Grand America Hotel
555 Main Street
Salt Lake City, UT 84111

Providers

Jointly Provided by the University of Utah, Intermountain Healthcare, and the North American Neuroendocrine Tumor Society

Course Directors

Heloisa Soares, MD, PhD, University of Utah and Mark Lewis, MD, Intermountain Healthcare

Overview

Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years, there was great variability in terms of treatment. The diagnosis, treatment, and management of NETs are time-consuming, complex, and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
• Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
• Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
• Recognize the clinical features associated with carcinoid syndrome
• Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
• Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors

Program

• • Heloisa P. Soares, MD, PhD, Associate Professor, Huntsman Cancer Institute (HCI), University of Utah

• • GEP-NETS: Background, epidemiology; pathologic principles, differentiation, grading; anatomic and functional imaging
    Pamela Kunz, MD, Associate Professor, Internal Medicine; Director, Center for Gastrointestinal Cancers, Smilow Cancer Hospital and Yale Cancer Center; Chief, GI Medical Oncology; Vice Chief, Diversity, Equity, and Inclusion, Medical Oncology, Yale School of Medicine
  • Lung and DIPNECH: Background, epidemiology, pathologic principles, differentiation, grading, anatomic and functional imaging
    Sonam Puri, MD, Assistant Professor, Division of Oncology, University of Utah

• • Dealing with SBNETs
    Callisia N. Clarke, MD, MS, FACS, FSSO, Associate Professor and Chief, Medical College of Wisconsin
  • Not all Gastric and Duodenal NETs are the same, how to manage localized  Gastric and Duodenal NETs
    Erin P. Ward, MD, Assistant Professor, University of Utah
  • When and how extensively to resect a PNETs
    Courtney L. Scaife, MD, Professor of Surgery, University of Utah
  • Resection of the primary Tumor in Stage IV Disease SB and PNET?
    Alexandra Gangi, MD, Director, Gastrointestinal Tumor Program, Surgical Oncology, Department of Surgery, Cedars-Sinai

• • Somatostatin analogs and targeted drugs
    Ramya Thota, MD, GI Medical Oncologist, Intermountain Medical Center
  • When to use cytotoxic chemotherapy
    Thorvardur (Thor) R. Halfdanarson, MD, Professor of Oncology, Mayo Clinic
  • Peptide receptor radionuclide therapy (PRRT) indications and challenging scenarios
    Jonathan R. Strosberg, MD, Medical Oncology, Moffitt Cancer Center
  • Clinical trials/emerging treatments
    Heloisa P. Soares, MD, PhD, Associate Professor, Huntsman Cancer Institute (HCI), University of Utah

• • TAE vs. TACE vs. TARE: pros and cons
    Michael C. Soulen, MD, Director of Research, Interventional Radiology, University of Pennsylvania
  • Ablation modalities and indications
    Ziga Cizman, MD, MPH, Associate Professor, Interventional Radiology. University of Utah School of Medicine and Huntsman Cancer Institute (HCI)
  • Liver debulking
    Julie Hallet, MD, MSc, FRCSC, Associate Scientist, Sunnybrook Health Sciences Centre
  • MultiD panel discussion about liver-only disease: LDT vs PRRT vs Surgery vs Transplant

• • Symptom control strategies
    Simron Singh, MD, MPH, FRCPC, Medical Oncology, Odette Cancer Center at Sunnybrook Health Sciences Center
  • Carcinoid Heart Disease
    Ross A. Butschek, MD, Cardiologist, Intermountain Medical Center
  • Techniques for heart surgery
    Vikas Sharma, MD, Assistant Professor of Surgery, Division of Cardiothoracic Surgery, University of Utah

• • First-line metastatic treatment, Role of immunotherapy, Multimodality treatment of locoregional disease
    Aman Chauhan, MD, Assistant Professor of Medicine, Director of Neuroendocrine Cancer Program, Sylvester Cancer Center
    University of Miami

• • Hereditary syndromes overview
    Mark A. Lewis, MD, Director of Gastrointestinal Oncology, Intermountain Medical Center
  • Management of PPG/Pheos- Surgical Management
    Fiemu E. Nwariaku, MD, FACS, MBA, Professor and Chair, Department of Surgery, Spencer Fox Eccles School of Medicine, University of Utah
  • Systemic management
    Jaydira Del Rivero, MD, Physician Scientist, Developmental Therapeutics Branch, National Institutes of Health

 Register Now

Accreditation

This continuing education activity is provided through collaboration between the North American Endocrine Tumor Society (NANETS) and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurse practitioners, and nurses. A statement of participation is available for other attendees.

Physicians, Physician Assistants, and Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the NANETS. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians for ABIM Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation enables the participant to earn up to 6.50 Medical Knowledge only MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Use of Learner/Participant Data

Participation information will be shared with the applicable certifying board via ACCME PARS.

In order for MOC credit to be reported, evaluations must be completed prior to the close of evaluations.

Nurses

Continuing Nursing Education is provided for this program through the joint providership of AffinityCE and NANETS. AffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC). This activity provides a maximum of 6.50 hours of continuing nursing education credit.

Registration fee:

NANETS Member

$65 - MD, PharmD, Doctoral Level 
$35 - Allied Health
Complimentary - Student/Fellow/Resident

Non-Member

$95 - MD, PharmD, Doctoral Level 
$50 - Allied Health
Complimentary - Student/Fellow/Resident

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before October 13, 2023. On or after October 14, 2023, no refund will be made.

University of Utah, Intermountain Healthcare, and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.

Questions?

Please contact us with any questions.